Evaxion Biotech AS

Yahoo Finance • 3 days ago

European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading

European equities traded in the US as American depositary receipts started the week modestly lower l PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 9 days ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO has commencedThomas Schmidt appointed permanent Chief Financial Officer COPENHAGEN, Denmark, J... Full story

Yahoo Finance • 13 days ago

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 2.5% for Week

European equities traded in the US as American depositary receipts were tracking higher late Friday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 14 days ago

Evaxion Adds GAS Vaccine Candidate EVX-B4 To Pipeline Using AI-Immunology Platform

(RTTNews) - Evaxion Biotech A/S (EVAX) announced the expansion of its vaccine pipeline with the addition of EVX-B4, a novel vaccine candidate targeting Group A Streptococcus or GAS. This new program is powered by the company's proprietary... Full story

Yahoo Finance • 15 days ago

Evaxion to develop new vaccine against Group A Streptococcus

COPENHAGEN - Biotech company Evaxion A/S (NASDAQ:EVAX), currently valued at $15.5 million and showing strong momentum with a 13% gain last week, announced on Wednesday it has initiated development of a preventive vaccine against Group A St... Full story

Yahoo Finance • 15 days ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Initial computational analysis demonstrated that Evaxion’s AI-Immunology™ platform can identify novel vaccine targets to combatGroup A Streptococcus (GAS)New vaccine program is added to Evaxion’s pipeline under the name EVX-B4Urgent need f... Full story

Yahoo Finance • 16 days ago

European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading

European equities traded in the US as American depositary receipts were softer late Monday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 23 days ago

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking lower late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • last month

Evaxion receives grant funding to design new polio vaccine

Evaxion awarded a grant from the Gates FoundationGrant funds research aimed at ultimately eradicating polio, a highly infectious viral diseaseEvaxion will apply its leading AI-Immunology™ platform to identify and combine various antigens t... Full story

Yahoo Finance • last month

Evaxion announces business update and first quarter 2025 financial results

COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2025 financial re... Full story

Yahoo Finance • 2 months ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 finan... Full story

Yahoo Finance • 2 months ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data packageWill provide insights into the durability of immune and clinical... Full story

Yahoo Finance • 3 months ago

Evaxion to present at World Vaccine Congress

Congress will take place April 21-24, 2025, in Washington, D.C. COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vacci... Full story

Yahoo Finance • 3 months ago

Evaxion announces business update and full year 2024 financial results

COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financi... Full story

Yahoo Finance • 3 months ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024... Full story

Yahoo Finance • 3 months ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting These data will further add to the already strong clinical data package for EV... Full story

Yahoo Finance • 4 months ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further insights into potential enhanced treatment... Full story

Yahoo Finance • 5 months ago

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders’ equity requirement Evaxion has restored its equity above the minimum requirement through capital market activitiesEvaxion’s... Full story

Yahoo Finance • 5 months ago

Evaxion announces closing of $10.8 million public offering

COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an agg... Full story

Yahoo Finance • 5 months ago

Evaxion announces pricing of $10.8 million public offering

COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an agg... Full story